Dupilumab Among Patients with Uncontrolled Severe Asthma in China: A Cost-Utility Analysis
Based on the current Chinese healthcare system, it was not cost-utility to apply dupilumab as an add-on therapy for patients aged ≥12 years with uncontrolled severe asthma. A substantial price reduction of dupilumab could improve affordability in this patient population.
Authors
- Xintian Shen (ORCID: https://orcid.org/0000-0003-0626-4317)
- Jinzhen Huang (ORCID: https://orcid.org/0000-0002-0274-0454)
- X. Ye (ORCID: https://orcid.org/0009-0009-7884-6181)
- Huifang Zhu (ORCID: https://orcid.org/0000-0003-0303-7522)
- Xiaomei Fan (ORCID: https://orcid.org/0000-0001-8251-7035)
- Maosheng Xu
- Zheng Liu (ORCID: https://orcid.org/0000-0001-5740-2551)
Institutions
- Panyu Hospital of Chinese Medicine (CN)
- Shenzhen Bao'an District People's Hospital (CN)
- Guangdong Province Women and Children Hospital (CN)
- Shenzhen Children's Hospital (CN)
Publication Details
- Journal
- Journal of Asthma and Allergy
- Published
- 2025-10-01
- DOI
- https://doi.org/10.2147/jaa.s545324
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Guangdong Province
- Chinese Pharmaceutical Association